182 related articles for article (PubMed ID: 35037146)
41. Therapeutic Stalemate in Heart Failure With Preserved Ejection Fraction.
Samson R; Le Jemtel TH
J Am Heart Assoc; 2021 Jun; 10(12):e021120. PubMed ID: 34056916
[TBL] [Abstract][Full Text] [Related]
42. Heart Failure with Preserved Ejection Fraction-a Concise Review.
Adamczak DM; Oduah MT; Kiebalo T; Nartowicz S; Bęben M; Pochylski M; Ciepłucha A; Gwizdała A; Lesiak M; Straburzyńska-Migaj E
Curr Cardiol Rep; 2020 Jul; 22(9):82. PubMed ID: 32648130
[TBL] [Abstract][Full Text] [Related]
43. DYRK1B-STAT3 Drives Cardiac Hypertrophy and Heart Failure by Impairing Mitochondrial Bioenergetics.
Zhuang L; Jia K; Chen C; Li Z; Zhao J; Hu J; Zhang H; Fan Q; Huang C; Xie H; Lu L; Shen W; Ning G; Wang J; Zhang R; Chen K; Yan X
Circulation; 2022 Mar; 145(11):829-846. PubMed ID: 35235343
[TBL] [Abstract][Full Text] [Related]
44. Bendavia, a mitochondria-targeting peptide, improves postinfarction cardiac function, prevents adverse left ventricular remodeling, and restores mitochondria-related gene expression in rats.
Dai W; Shi J; Gupta RC; Sabbah HN; Hale SL; Kloner RA
J Cardiovasc Pharmacol; 2014 Dec; 64(6):543-53. PubMed ID: 25165999
[TBL] [Abstract][Full Text] [Related]
45. Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF.
Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Legg JC; Büchele G; Varin C; Kurtz CE; Malik FI; Honarpour N
JACC Heart Fail; 2020 Apr; 8(4):329-340. PubMed ID: 32035892
[TBL] [Abstract][Full Text] [Related]
46. Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.
Omar M; Jensen J; Ali M; Frederiksen PH; Kistorp C; Videbæk L; Poulsen MK; Tuxen CD; Möller S; Gustafsson F; Køber L; Schou M; Møller JE
JAMA Cardiol; 2021 Jul; 6(7):836-840. PubMed ID: 33404637
[TBL] [Abstract][Full Text] [Related]
47. Study of muscular and ventricular function in dynamic cardiomyoplasty: a ten-year follow-up.
Chachques JC; Berrebi A; Hernigou A; Cohen-Solal A; Lavergne T; Marino JP; D'Attellis N; Bensasson D; Carpentier A
J Heart Lung Transplant; 1997 Aug; 16(8):854-68. PubMed ID: 9286778
[TBL] [Abstract][Full Text] [Related]
48. Study protocol, randomized controlled trial: reducing symptom burden in patients with heart failure with preserved ejection fraction using ubiquinol and/or D-ribose.
Pierce JD; Mahoney DE; Hiebert JB; Thimmesch AR; Diaz FJ; Smith C; Shen Q; Mudaranthakam DP; Clancy RL
BMC Cardiovasc Disord; 2018 Apr; 18(1):57. PubMed ID: 29606104
[TBL] [Abstract][Full Text] [Related]
49. Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure.
Mishima T; Tanimura M; Suzuki G; Todor A; Sharov VG; Goldstein S; Sabbah HN
J Am Coll Cardiol; 2000 Jan; 35(1):222-9. PubMed ID: 10636284
[TBL] [Abstract][Full Text] [Related]
50. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure.
Suzuki G; Morita H; Mishima T; Sharov VG; Todor A; Tanhehco EJ; Rudolph AE; McMahon EG; Goldstein S; Sabbah HN
Circulation; 2002 Dec; 106(23):2967-72. PubMed ID: 12460880
[TBL] [Abstract][Full Text] [Related]
51. Heart failure with preserved ejection fraction: insights from recent clinical researches.
Kim MN; Park SM
Korean J Intern Med; 2020 May; 35(3):514-534. PubMed ID: 32392659
[TBL] [Abstract][Full Text] [Related]
52. Elamipretide (SS-31) Ameliorates Isoflurane-Induced Long-Term Impairments of Mitochondrial Morphogenesis and Cognition in Developing Rats.
Wu J; Hao S; Sun XR; Zhang H; Li H; Zhao H; Ji MH; Yang JJ; Li K
Front Cell Neurosci; 2017; 11():119. PubMed ID: 28487636
[TBL] [Abstract][Full Text] [Related]
53. Is remodeling the dominant compensatory mechanism in both chronic heart failure with preserved and reduced left ventricular ejection fraction?
MacIver DH
Basic Res Cardiol; 2010 Mar; 105(2):227-34. PubMed ID: 19779757
[TBL] [Abstract][Full Text] [Related]
54. Elamipretide as a potential candidate for relieving cryodamage to human spermatozoa during cryopreservation.
Bai H; Zhang Y; Tian S; Hu R; Liang Y; Gao J; Wang Y; Wu B
Cryobiology; 2020 Aug; 95():138-142. PubMed ID: 32240641
[TBL] [Abstract][Full Text] [Related]
55. Targeting Metabolic Modulation and Mitochondrial Dysfunction in the Treatment of Heart Failure.
Steggall A; Mordi IR; Lang CC
Diseases; 2017 May; 5(2):. PubMed ID: 28933367
[TBL] [Abstract][Full Text] [Related]
56. Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction.
Udelson JE; DeAbate CA; Berk M; Neuberg G; Packer M; Vijay NK; Gorwitt J; Smith WB; Kukin ML; LeJemtel T; Levine TB; Konstam MA
Am Heart J; 2000 Mar; 139(3):503-10. PubMed ID: 10689266
[TBL] [Abstract][Full Text] [Related]
57. Ketone Ester Treatment Improves Cardiac Function and Reduces Pathologic Remodeling in Preclinical Models of Heart Failure.
Yurista SR; Matsuura TR; Silljé HHW; Nijholt KT; McDaid KS; Shewale SV; Leone TC; Newman JC; Verdin E; van Veldhuisen DJ; de Boer RA; Kelly DP; Westenbrink BD
Circ Heart Fail; 2021 Jan; 14(1):e007684. PubMed ID: 33356362
[TBL] [Abstract][Full Text] [Related]
58. Effect of l-arginine on cardiac reverse remodeling and quality of life in patients with heart failure.
Salmani M; Alipoor E; Navid H; Farahbakhsh P; Yaseri M; Imani H
Clin Nutr; 2021 May; 40(5):3037-3044. PubMed ID: 33610421
[TBL] [Abstract][Full Text] [Related]
59. Effects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results From Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE).
St John Sutton M; Cerkvenik J; Borlaug BA; Daubert C; Gold MR; Ghio S; Chirinos JA; Linde C; Ky B
J Am Heart Assoc; 2015 Sep; 4(9):e002054. PubMed ID: 26363005
[TBL] [Abstract][Full Text] [Related]
60. Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction.
Voors AA; Shah SJ; Bax JJ; Butler J; Gheorghiade M; Hernandez AF; Kitzman DW; McMurray JJV; Wirtz AB; Lanius V; van der Laan M; Solomon SD
Eur J Heart Fail; 2018 Nov; 20(11):1601-1610. PubMed ID: 30225882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
